Search PubMed⌕ Search

Biomedical subjects

J Stasiewicz

Publications and source records attributed to J Stasiewicz.

At least 37 records · Page 2Linked to original sources
PubMed1989

Gastric cancer with special references to WHO and Laurén's classifications: glycogen and triacylglycerol concentrations in the tumor.

In eighty patients with histologically verified gastric carcinoma the concentrations of glycogen and triacylglycerols were evaluated in specimens taken endoscopically from the tumor and the surrounding unchanged gastric mucosa. The results were analyzed in relation to the histological type of carcinoma according to WHO's and Laurén's classifications. The control group consisted of sixteen patients with superficial chronic gastritis. An elevated glycogen concentration was found in tumors of all types of gastric carcinoma; its level in the neoplasm was significantly higher also in relation to unchanged gastric mucosa surrounding the tumor. A particularly high glycogen level was present in the slow growing well-differentiated cancers, e.g. papillary and tubular adenocarcinomas or intestinal-type carcinoma. Reversely, in the fast growing and poorly differentiated cancers, e.g. undifferentiated or diffuse-type carcinoma, the glycogen contents were lower. Also triacylglycerol concentrations in the tumors as well as in the surrounding unchanged gastric mucosa were significantly higher than those in the control gastric mucosa specimens; no significant difference in triacylglycerol concentrations was observed between groups of patients with various types of carcinoma. It was concluded that (1) glycogen concentrations in the neoplastic tissue are cancer-growth related and characteristic for each kind of carcinoma, (2) an elevated triacylglycerol content in the tumor is probably a result of general lipid changes in the host.

Adenocarcinoma↗
PubMed1988

Calcitonin versus cimetidine or De-Nol in gastric ulcer treatment. An endoscopically controlled trial.

110 patients with benign gastric ulcer and concomitant joint diseases (rheumatoid arthritis, osteoarthrosis) were treated in a comparative short-term clinical trial to assess the relative efficacy of calcitonin (daily 100 MRC of salmon calcitonin intramuscularly), cimetidine (daily 1000 mg orally) and colloidal bismuth subcitrate (De-Nol-four times a day in doses of 5 ml diluted with 15 ml of water). Groups of patients were comparable according to age, sex, duration of ulcer disease, smoking habits, gastric acid secretion and mean ulcer size. The ulcer healing was controlled endoscopically after 2 and 4 weeks of the treatment. There was no significant difference in the ulcer healing rate between three groups neither after 2 weeks (calcitonin-36.7% of healed ulcers, cimetidine-37.5% and De-Nol-35.0% nor after 4 weeks respectively (76.7%, 72.5% and 77.5%). In the calcitonin group a gradual joint pain relief was observed in 84% of patients who complained arthralgia. The moderate side effects (headache, nausea, flush) were observed only in the patients treated with calcitonin (8 subjects). We suggest that calcitonin may be considered as a valid anti-ulcer drug in the peptic ulcer patients with concomitant rheumatological diseases especially with osteoporosis.

Administration, Oral↗